ライフサイエンスコーパス: i.m.

1 i.m. injection of AS01 enhances immune cell activation a

2 i.m. inoculation was inferior to i.n. inoculation at ind

3 i.m. inoculation with inactivated EDIM, cell culture-ada

4 i.m. inoculation with live, wild-type rotavirus (murine

5 e injected a plasmid DNA encoding TGF-beta 1 i.m. to the SCW animals to determine the effect of TGF-b

6 plasma triglycerides by 38% (i.p.) and 26% (i.m.) was obtained.

7 ty in skeletal muscle by 58% (i.p.) and 36% (i.m.) when compared with control-injected mice.

8 Although most vaccines are administered i.m., little is known about the dendritic cells (DCs) th

9 .m.; group B), or 7.2 mg of DNA administered i.m. (high-dose group C) each time.

10 Dexamethasone was administered i.m. to pregnant ewes as 3 weekly courses (4 x 2 mg at 1

11 mg/kg M100+0.3 mg/kg WAY) were administered i.m. before lights-out.

12 After i.m. administration of Ag adsorbed to alum, we showed th

13 After i.m. immunization, the microparticles induced significan

14 s I MHC presentation of viral antigens after i.m. immunization with plasmid DNA.

15 rbed DNA into antigen-presenting cells after i.m. injection.

16 Three days after i.m. immunization with rotavirus, cells obtained from th

17 heart, lung, liver, and spleen 7 days after i.m. injection of p21 sense plasmid DNA.

18 and the immunogenicity was determined after i.m. immunization in combination with in vivo electropor

19 e responses to AAV capsid that develop after i.m. injection of a serotype 1 rAAV vector expressing AA

20 he predominant site of gene expression after i.m. immunization of plasmid DNA, but it is not clear if

21 pable of contributing to muscle fibers after i.m. injection.

22 gut-associated lymphoid tissue (GALT) after i.m. immunization.

23 of response was significantly greater after i.m. jet injection.

24 at 1, 2, 4, 8, 24, 48, 120, and 168 h after i.m. injection of 30 micro g of IFN-beta-1a.

25 rsely, the highest transfection levels after i.m. administration were achieved with naked DNA, follow

26 mune response in the lymphatic network after i.m. and s.c. injection of a clinically relevant vaccine

27 s formed invasive soft tissue sarcomas after i.m. injection into nude or scid mice.

28 ent and highly localized to the tissue after i.m. injection; it caused an increase in the number of A

29 fter i.p. immunization, as compared to after i.m. immunization.

30 ine induced significant local toxicity after i.m. injection, whereas C32 demonstrated no toxicity.

31 CD86 cDNA along with DNA encoding HIV-1 Ags i.m. dramatically increased Ag-specific CTL responses.

32 (oral group), intramuscularly (i.m.) alone (i.m. group), orally followed by i.m. (oral/i.m. group),

33 An i.m. or an intradermal administration of HSV:gp120 at th

34 boosted with Ad5.RSV-F i.n. 28 days after an i.m. dose also had significant increases in neutralizing

35 After an i.m. modified vaccinia Ankara/Gag boost, we observed rob

36 ing in the lymphatic vessels that connect an i.m. injection site with the local lymph node has not be

37 -PsVs expressing SIV genes, combined with an i.m. gp120 protein injection, induced humoral and cellul

38 rved that vaccination of BALB/c mice with an i.m. HBsAg-DNA vaccine prime followed by an intranasal b

39 d out in an athymic nude mouse model with an i.m. xenograft of LNCaP cells.

40 me-boost vaccination via sequential s.c. and i.m. administration yielded greater efficacy than any ot

41 ccination combining ivag HPV-gBsec/gDsec and i.m. gD2t-alum-MPL improved survival and reduced genital

42 33R, and B5R proteins by the intradermal and i.m. routes, either alone or in combination with the equ

43 xicity and DNA delivery after intratumor and i.m. injection.

44 ntramuscular (i.m.) immunization of mice and i.m. immunization of rabbits with formalinized staphyloc

45 Repeated intraperitoneal (i.p.) and i.m. DNA administration increased the LPL activity in sk

46 DNA, intramuscularly (i.m.) in one study and i.m. and subcutaneously in another study.

47 icroneedle-based device is as efficacious as i.m. vaccination.

48 e immunized through different routes such as i.m., intradermally, or intratracheally with a DNA vacci

49 resting period, these macaques were boosted i.m. with the live-attenuated trachoma vaccine and their

50 In addition, both i.m. and i.n. plasmid immunizations failed to generate a

51 The capacity of proteosomes to enhance both i.m. and intranasal immunogenicity and efficacy of SEB t

52 ice (Biojector) to deliver 1800 micro g both i.m. and intradermally (i.d.); 9 of 12 patients had humo

53 g mouse endostatin plus angiostatin (E+A) by i.m. injection.

54 by intradermal injection of pAra h2, and by i.m. injection of pOMC, the plasmid DNA encoding the maj

55 IFN-omega pDNA delivered by i.m. injection also had an antitumor effect.

56 ged into serotype 1 AAV capsids delivered by i.m. injection.

57 g properties distinct from those elicited by i.m. or i.n. rAd immunization.

58 i.m.) alone (i.m. group), orally followed by i.m. (oral/i.m. group), or i.m. followed by orally (i.m.

59 evels of interleukin-2 than those induced by i.m. immunization.

60 Ab response to beta-galactosidase induced by i.m. or intradermal injection of placZ, a plasmid DNA ve

61 However, when infection was initiated by i.m., i.v., or i.p. routes, only a subset of the members

62 s from deer mice (Peromyscus maniculatus) by i.m. inoculation of 4- to 6-wk-old deer mouse pups.

63 to the antigen than immunization of mice by i.m. injection with the same plasmid did.

64 DNA immunization efficacy was optimized by i.m. delivery via electroporation, yet it remained modes

65 se coinjection reduces CD4 T-cell priming by i.m. injected antigen + alum.

66 static tumors can be treated systemically by i.m. injection of a plasmid encoding a cytokine gene.

67 contrast, using the i.m.-subcutaneous (s.c.)-i.m. regimen, it was found that gp120 and CTLA4:gp120 DN

68 In comparison, i.m. injection of alphaS fibrils was more efficient in i

69 ewes received dexamethasone (2 x 12 mg daily i.m. injections in saline).

70 intoxication, i.e., the previously described i.m. challenge model and a new respiratory challenge mod

71 Direct i.m. injection of IL-12 cDNA induced activation of resti

72 Mice were injected with the naked DNA i.m., and immune responses were compared to those elicit

73 red to 263/331 (79%) receiving the five-dose i.m. regimen, showing non-inferiority of the simplified

74 col population was 1,002 children (five-dose i.m.: n = 331; three-dose i.m.: n = 338; three-dose i.v.

75 We compared both a three-dose i.m. and a three-dose i.v. parenteral ARS regimen with t

76 In the three-dose i.m. arm, 265/338 (78%) children had a >/= 99% reduction

77 A simplified three-dose i.m. regimen for severe malaria in African children is n

78 hildren (five-dose i.m.: n = 331; three-dose i.m.: n = 338; three-dose i.v.: n = 333); 139 participan

79 nderstanding of the role of adjuvants during i.m. vaccination needs to take into account the heteroge

80 DNA vaccines are usually administered either i.m. or intradermally.

81 tions of 4 mg/kg (at 0, 24, and 48 h) either i.m. (n = 348) or i.v. (n = 351), both of which were the

82 s were also seen between CRs given Ad5.RSV-F i.m. and CRs given Ad5.RSV-F i.n.

83 Consistent with these findings, i.m. injection of the gp120/GM-CSF bicistronic DNA vacci

84 g/kg ARS as either a control regimen of five i.m. injections of 2.4 mg/kg (at 0, 12, 24, 48, and 72 h

85 s and antigen-specific CD4 T cells following i.m. injection.

86 systemic and mucosal compartments following i.m. immunization in 12 low- and high-risk HIV-1 seroneg

87 This effect is less dramatic following i.m. infection and is minimal after s.c. or intradermal

88 f the stability of gene expression following i.m. injection of RDAd.

89 y of CTL precursors (CTLp) in mice following i.m. injection with NP DNA or intranasal infection with

90 odies elicited to the SERA protein following i.m. and Gene Gun immunizations with SERA plasmid DNA wa

91 did not mount Ab or CTL responses following i.m. immunization with eukaryotic expression plasmids en

92 ependencies on the injection site tissue for i.m. needle and epidermal gene gun DNA immunizations.

93 Furthermore, i.m. injection of soluble, nonaggregated alphaS in M83(+

94 Furthermore, i.m. or intradermal coinjection of pCD40L with placZ enh

95 Proteosome-toxoid plus alum given i.m. also elicited more significant protection against r

96 seen in CRs vaccinated with Ad5.RSV-F given i.m. or i.n., and these responses correlated with reduce

97 In contrast, resistant B10.D2 mice given i.m. injections with a recombinant adenovirus-expressing

98 8.2-fold greater than the same vaccine given i.m.), a response that could not be matched by antigen m

99 The high i.m. dose induced the responses of the greatest magnitud

100 Mice immunized i.m. with pB5 generated an antibody response that reduce

101 Negative-control groups were immunized i.m. and s.c. with Neisseria gonorrhoeae recombinant por

102 cally susceptible BALB/c mice were immunized i.m. with DNA for one or two Mycoplasma pulmonis Ags (A7

103 ring 7.6-8-mm MCa-4 mammary tumors implanted i.m. into the right posterior thigh.

104 s.c. A431 epidermoid carcinoma and injected i.m. with 100 microg of IFN-omega pDNA, twice per week f

105 When RiVax was injected i.m. into mice it protected them against a ricin challen

106 Whether RDAd vectors were injected i.m. or i.v. or through an i.p. route, the extent of lys

107 melanoma, or glioma 261 tumors were injected i.m. with mIFN-alpha pDNA.

108 by needle i.m. or needleless jet injection [i.m. or i.m./intradermally (i.d.)] in 14 volunteers.

109 ce than RH30-S cells and (b) mice inoculated i.m. with the RH30-L cells had more rhabdomyosarcoma cel

110 Intramuscular (i.m.) injection of mice showed that each construction in

111 , intraperitoneal (i.p.), and intramuscular (i.m.) routes of injection of alphaS fibrils and other pr

112 urrent intradermal (i.d.) and intramuscular (i.m.) vaccinations as a DNA-priming strategy for their a

113 ompared to those generated by intramuscular (i.m.) gB DNA and i.n. live HSV administration.

114 gnitude to those generated by intramuscular (i.m.) immunization.

115 mid DNA vaccines delivered by intramuscular (i.m.) injection or delivered intradermally by Gene Gun i

116 Once daily intramuscular (i.m.) injection for 3 d would be simpler and more approp

117 ion strategies were employed: intramuscular (i.m.), intranasal (i.n.) at a low dose and low volume, a

118 mmunocompetent mice following intramuscular (i.m.) injection with identical RDAd encoding self (murin

119 Following intramuscular (i.m.), intranasal (i.n.), or intravaginal (IVAG) immuniz

120 ng experimental inflammation (intramuscular (i.m.) typhoid vaccination) and once after placebo (i.m.

121 but clinical trials involving intramuscular (i.m.) injection of HSV-2 gB and gD in adjuvants have not

122 o mice via intranasal (i.n.), intramuscular (i.m.), and oral inoculation.

123 investigated the capacity of intramuscular (i.m.) immunization with heterologous-host rotavirus (sim

124 The capacity of intramuscular (i.m.) inoculation of mice with homologous or heterologou

125 s after intradermal (i.d.) or intramuscular (i.m.) delivery of 0.5 to 1 mg of codon-optimized DNA enc

126 Intranasal or intramuscular (i.m.) immunization of mice and i.m. immunization of rabb

127 Intranasal or intramuscular (i.m.) immunization with formalinized SEB toxoid formulat

128 ntradermal (i.d.) delivery or intramuscular (i.m.) injection using conventional needles.

129 via the intranasal (i.n.) or intramuscular (i.m.) route in different prime-boost combinations.

130 d vaccinia Ankara (MVA) prime/intramuscular (i.m.) protein boost regimen induced functional IgG respo

131 tudies revealed that a single intramuscular (i.m.) injection of 10(6) infectious units (i.u.) of HSV:

132 Here we report that a single intramuscular (i.m.) injection of a nonreplicating adenovirus (Ad) vect

133 A single intramuscular (i.m.) injection of as little as 10 micrograms of this pl

134 egimens incorporated a single intramuscular (i.m.) injection of the DNA vaccines to prime the immune

135 After single intramuscular (i.m.) injections, human lipoprotein lipase (hLPL) mRNA w

136 ytokine profiling reveal that intramuscular (i.m.) administration of 1Z105 and 1V270 is less reactoge

137 c mice were vaccinated by the intramuscular (i.m.) and subcutaneous (s.c.) routes with a native prepa

138 of mice were immunized by the intramuscular (i.m.) and subcutaneous (s.c.) routes with recombinant MO

139 eas immunization via e.g. the intramuscular (i.m.) or subcutaneous (s.c.) routes often stimulate weak

140 G when delivered once via the intramuscular (i.m.) route.

141 sorbent assay following three intramuscular (i.m.) injections of pCMV-Tag and were typified by a mixe

142 ia the s.s. route compared to intramuscular (i.m.) injection as used in MVA clinical trials.

143 the sciatic nerve in mice via intramuscular (i.m.) injection, ELP-curcumin conjugates underwent a the

144 unization in conjunction with intramuscular (i.m.) vaccination provided full protection of hamsters f

145 e following hind limb muscle (intramuscular [i.m.]) injection of alphaS fibrils by comparing various

146 When administered intramuscularly (i.m.) to swine, there was no induction of disease, even

147 raginase (ASP) administered intramuscularly (i.m.) weekly for 24 weeks (regimen B); or regimen A plus

148 1.2 mg of DNA administered intramuscularly (i.m.; group B), or 7.2 mg of DNA administered i.m. (high

149 inoculated onto the cornea, intramuscularly (i.m.), intravaginally, and intracranially.

150 mutant SIV expressing DNA, intramuscularly (i.m.) in one study and i.m. and subcutaneously in anothe

151 bats were inoculated either intramuscularly (i.m.) or subcutaneously (s.c.) with a homologous or hete

152 orally alone (oral group), intramuscularly (i.m.) alone (i.m. group), orally followed by i.m. (oral/

153 wine, since pigs inoculated intramuscularly (i.m.) with either 10(2) or 10(4) 50% hemadsorbing doses

154 rorally (p.o.) (group 1) or intramuscularly (i.m.) (group 2) or three times i.m. (group 3) with inact

155 intranasally (i.n.) and/or intramuscularly (i.m.) and subsequently challenged with RSV/A/Tracy (i.n.

156 inant plasmids were used to intramuscularly (i.m.) immunize BALB/c mice.

157 vaccine regimens utilizing intramuscularly (i.m.) administered recombinant adenovirus (rAd)-based ve

158 h those treated with high-dose CsA (62 mg/kg i.m. on day 2), low-dose CsA (25 mg/kg), an endothelin-c

159 y, and that for dexamethasone was 0.61 mg/kg i.m. twice a day; the hCRF:dexamethasone dose-potency ra

160 th an iron chelator, deferoxamine, (50mg/kg, i.m.) or vehicle and killed at day-3 to examine the effe

161 Rats were treated with DFX (100 mg/ kg, i.m.) or vehicle immediately after tMCAO.

162 Administration of HA-966 (0.1-10 mg/kg, i.m.) 30 min before testing impaired DNMS performance do

163 Importantly, M100907 (0.3 mg/kg, i.m.) attenuated cocaine-induced (1.0 mg/kg, i.v.) dopam

164 7-NI (17.8 mg/kg, i.m.) completely generalized to PCP.

165 (saline, i.m.) or acute PCP (0.1-0.3 mg/kg, i.m.) conditions.

166 PCP (0.3 mg/kg, i.m.) exerted regionally selective effects on the dopami

167 ined to discriminate between PCP (1.0 mg/kg, i.m.) from saline in a two-key operant procedure.

168 t with previous studies, M100907 (0.3 mg/kg, i.m.) significantly attenuated drug- and cue-induced rei

169 hypothermia caused by WIN 55212-2 (5 mg/kg, i.m.), a cannabinoid agonist, was not significantly alte

170 ed by pretreatment with S-(-)HA966 (3 mg/kg, i.m.).

171 phy (PET) after administration (2 x 2 mg/kg, i.m., 4 h apart) of either amphetamine (Amp), n = 3, or

172 onvulsive dose of soman (77.7 micrograms/kg, i.m.).

173 Four weeks after the last i.m.-plus-s.c. immunization, mice were challenged in the

174 The i.m.-i.m.-i.m. regimen induced only modest levels of gp120-specifi

175 of human TIMP-4 by electroporation-mediated i.m. injection of naked TIMP-4 DNA stimulates tumorigene

176 zed to receive dexamethasone [fetuses: 6 mg, i.m. every 12 hr for four doses to mother; lambs: 0.01 m

177 CSP were evaluated by immunizing BALB/c mice i.m. or epidermally and by varying the number of immuniz

178 Vaccination of mice i.m. with HSV2-gD27 provided better inhibition of challe

179 gand (CD40L) monoclonal antibody (250 microg i.m.).

180 on after chemotherapy received three monthly i.m. injections of the DNA in three dose escalation coho

181 icient subjects at various doses by multiple i.m. injections.

182 AKR/J and BALB/c mice also received multiple i.m. pAra h2 immunizations.

183 subcutaneously (s.c.), intranasally (i.n.), i.m., or transcutaneously (t.c.).

184 VA prime/i.n. boost regimen received an i.n./i.m. combined C.1086 gp120 boost.

185 Thus, maternal i.n./i.m. combined immunization is a novel strategy to enhanc

186 a malaria DNA vaccine administered by needle i.m. or needleless jet injection [i.m. or i.m./intraderm

187 Neither p.o. nor i.m. inoculation conferred significant protection agains

188 Finally, pulmonary, but not i.m., plasmid DNA vaccination protected mice from a leth

189 Comparison of i.m. vaccinations with HSV2-gD27 versus gD2t in adjuvant

190 nd draining lymph nodes of mice than that of i.m. immunization.

191 One i.m. dose of Ad/VNA-Stx prevented fatal central nervous

192 In contrast, s.c. or i.m. immunization usually results in the formation of a

193 aining lymph nodes in vivo following s.c. or i.m. immunization.

194 mals, particularly when given by the s.c. or i.m. route.

195 A and OVA+CAF09 administered via the s.c. or i.m. routes.

196 ing the lymphatic compartments after s.c. or i.m. vaccination with AS01 administered with hepatitis B

197 eceived AVA by the s.q. (reference group) or i.m. route at 0, 2, and 4 weeks and 6 months (4-SQ or 4-

198 rally followed by i.m. (oral/i.m. group), or i.m. followed by orally (i.m./oral group).

199 e in vivo, we injected mice intradermally or i.m. with plasmid DNA encoding a MHC class I-restricted

200 In contrast, intranasal or i.m. immunization with toxoid in saline without proteoso

201 le i.m. or needleless jet injection [i.m. or i.m./intradermally (i.d.)] in 14 volunteers.

202 .n. administration of CT compared to i.n. or i.m. gB DNA or i.n. live HSV immunization.

203 Two or three immunizations via the i.n. or i.m. route induced a more potent systemic and mucosal im

204 Mice that were not protected (oral or i.m./oral) had increased levels of IgA in both sera and

205 essed by using sequential i.m. and rectal or i.m. vaccination regimens.

206 e-toxoid delivered intranasally in saline or i.m. with either saline or alum afforded significant pro

207 s, whereas naked DNA injected either i.v. or i.m. elicited only systemic responses.

208 mended regimen of five intravenous (i.v.) or i.m. injections over 4 d.

209 (i.m. group), orally followed by i.m. (oral/i.m. group), or i.m. followed by orally (i.m./oral group

210 after immunization through the i.m. or oral/i.m. route.

211 ral/i.m. group), or i.m. followed by orally (i.m./oral group).

212 of DNA plus phosphate-buffered saline (PBS) i.m. using a needleless Biojector device.

213 typhoid vaccination) and once after placebo (i.m. saline), with the aim of characterizing effects of

214 Monkeys (10 per group) were primed i.m. and given booster injections by either the i.m. or

215 We found that prior i.m. immunization enhanced the magnitude of mucosal viru

216 f food allergy, C3H/HeSn (C3H) mice received i.m. injections of pAra h2 plasmid DNA encoding one of t

217 bearing mice were irradiated after receiving i.m. injection of Ad.Egr-TNF at viral titers 20-100 time

218 Surprisingly, young NOD mice receiving i.m. injections of pDNA encoding insulin B chain-IgGFc w

219 nical hyperalgesia, here induced by repeated i.m. acid injection.

220 ng the mdx murine model of DMD with repeated i.m. injections of PDGF-BB.

221 (PC) and later tested under vehicle (saline, i.m.) or acute PCP (0.1-0.3 mg/kg, i.m.) conditions.

222 protection was assessed by using sequential i.m. and rectal or i.m. vaccination regimens.

223 Single i.m. injections of viral vector restored dystrophin prod

224 Here we show that a single i.m. acid injection in mice lacking SP signaling by dele

225 than 60% for at least 90 days after a single i.m. injection of 10 micrograms of pVRmEpo.

226 In this study, we show that a single i.m. injection of an adeno-associated viral (AAV) vector

227 t 4, 8, and 12 wk of age were given a single i.m. injection of rAAV-murine IL-10 (10(4), 10(6), 10(8)

228 n immunocompetent animals following a single i.m. injection of RDAd encoding a self protein.

229 A single i.m. injection of recombinant AAV (rAAV)-mutant human en

230 After a single i.m. injection of the DNA vaccine encoding an HIV gag p4

231 l immunity in the lung, and protection, than i.m. immunization.

232 We conclude that i.m. injection of plasmid DNA represents a viable nonvir

233 We previously found that i.m. inoculation of mice with the intestinal pathogen, r

234 Immunologic analysis indicated that i.m. immunization of mice with either vaccine construct

235 We have previously shown that i.m. administration of bacterially expressed murine hist

236 These results suggest that i.m. delivery of rAAV type 1-AAT (rAAV1-AAT) induces a T

237 Our findings suggest that i.m. fibrocytes most likely originate from infiltrating

238 The i.m. injected plasmid DNA remained localized to the site

239 The i.m. injection of pNeuTM or pNeuE, and to a lesser exten

240 The i.m. route of immunization induced a strong IgG response

241 The i.m.-i.m.-i.m. regimen induced only modest levels of gp1

242 (CY) injection of C57BL/6J mice bearing the i.m. 76-9 rhabdomyosarcoma resulted in a significant pro

243 taneous administration of plasmid DNA by the i.m. and i.d. routes.

244 hepatitis B surface antigen (pCMV-s) by the i.m. route resulted in higher anti-SERA titers than thos

245 i.n. route was more immunogenic than by the i.m. route, and the same was true for the boosts.

246 . and given booster injections by either the i.m. or intratracheal route without adverse side effects

247 r extent than protein boosting by either the i.m., i.n., or t.c. route, suggesting that this route ma

248 tor-1 (IGF-1) promotes FP engraftment in the i.m. site and reversal of diabetes in a rodent model.

249 In the i.m.-gene gun (g.g.)-g.g. regimen, the mice immunized wi

250 hioglycolate-induced peritonitis models, the i.m. treatment with xylazine or UK14304, two alpha2-adre

251 mmature dendritic cells and suggest that the i.m. APCs may be enhancing immune responses to coinjecte

252 rved 3 months after immunization through the i.m. or oral/i.m. route.

253 ncement may depend on APC recruitment to the i.m. site of injection.

254 rrent HIV vaccines under development use the i.m. route for immunization, which is relatively poor in

255 In contrast, using the i.m.-subcutaneous (s.c.)-i.m. regimen, it was found that

256 tion of p21 was accomplished in mice via the i.m. injection of p21 sense plasmid DNA complexed with c

257 ngle dose of 10(8) PFU of rPIV5-RV-G via the i.m. route showed very robust protection (90% to 100%).

258 Thus, i.m. SP mediates an unconventional NK1 receptor signal p

259 Thus, i.m. vaccination can overcome immune compartmentalizatio

260 ramuscularly (i.m.) (group 2) or three times i.m. (group 3) with inactivated Wa strain human rotaviru

261 nducing mucosal antibody, it was inferior to i.m. DNA delivery in providing protection against lethal

262 tivation of p38 and the STATs in response to i.m. injection of IFN-beta1a or stimulation in vitro.

263 utputs were collected over 3 h subsequent to i.m. administration of KOR agonists.

264 IgG subclass bias were induced subsequent to i.m. DNA immunization.

265 Two i.m. immunizations with proteosome-toxoid plus alum also

266 g SIV Env, Rev, Gag, and Nef followed by two i.m. boosts with monomeric SIV gp120 or oligomeric SIV g

267 f pulmonary metastasis was achieved upon two i.m. injections of pCMV-Tag, as assessed by examination

268 Unexpectedly, i.m. immunization without adjuvant conferred the highest

269 mg each of the gp120 protein boost vaccine (i.m.).

270 axfectin i.d., 100 mug of DNA plus Vaxfectin i.m. or 100 mug of DNA plus phosphate-buffered saline (P

271 70 microg/kg estradiol cypionate or vehicle i.m. once a week.

272 s demonstrate the superiority of i.n. versus i.m. vaccination in protection against both lethal chall

273 ls of antibody similar to those produced via i.m. injection during the first 2 weeks following primar

274 We examined whether i.m. injection of either of these plasmids could induce

275 The mechanisms by which i.m. inoculation induces virus-specific humoral immune r

276 A cancer treatment is described in which i.m. injection of plasmid DNA (pDNA) encoding murine int

277 otection from aerosol spore challenge, while i.m. injection of the same dose provided slightly lower

278 enge with NFSA(MART1) could be achieved with i.m. injections of a MART-1 expression plasmid or with s

279 profibrotic growth factors as compared with i.m. fibroblasts.

280 Priming systemic immune responses with i.m. immunization with ALVAC-SIV vaccines, followed by i

281 mice in the control groups, with or without i.m. injection of a control vector AAV-GFP, died because

282 d alefacept (two 12-week courses of 15 mg/wk i.m., separated by a 12-week pause) with placebo in pati